The patent term for Namenda has been extended through April 10, 2015, according to Forest Laboratories. The medication is used to help treat people with Alzheimer’s disease. The patent had earlier ...

Memantine, a drug typically used to treat symptoms of Alzheimer's disease (AD), is linked to a significant reduction in symptoms of trichotillomania and skin-picking disorder, new research shows.

NEW YORK (Reuters) - Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the ...

The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...

Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) N-methyl ...

Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—contact supplier; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x ...

ATLANTA — Adding the Alzheimer drug memantine (Namenda, Allergan) to treatment with a selective serotonin reuptake inhibitor may improve depressive symptoms, executive function, and other outcomes in ...

(CN) - Actavis cannot maintain its billion-dollar monopoly on an Alzheimer's drug by forcing Alzheimer's patients to switch to a freshly patented version before a generic can enter the market, a 2nd ...

A federal appeals court confirmed an earlier ruling on Friday that Actavis must keep Alzheimer’s drug Namenda IR, an older formulation of Namenda XR, on the market. New York State Attorney General ...

You have full access to this article via your institution. In June 2000, Merz and Forest announced a development and marketing agreement for memantine in the United States for the treatment of AD and ...

Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer's medication ...